– Integrated Clinical Technology Portfolio to Maximize Efficiency and Manageability for Pivotal Study –
February 28, 2012. NEWTOWN, PA – BioClinica®, Inc., (NASDAQ: BIOC), a global provider of clinical trial management solutions, today announced that Amarin Corporation plc has chosen the eClinical suite from BioClinica to capture and manage clinical data for their Phase IIIb cardiology clinical trial, including: electronic data capture (EDC) and data management, interactive response technology (IRT/IVR/IWR), and clinical trial management (CTMS) solutions. Amarin Corporation is a late-stage biopharmaceutical company focused on the treatment of cardiovascular disease. The study is planned to involve approximately 300 sites and 8,000 patients globally.
BioClinica's Trident IWR and EDC systems were selected based on BioClinica's advanced technology portfolio, experience with large global trials; and cardiology expertise. BioClinica was able to build and deploy the study within 4 weeks.
"We are pleased that Amarin's clinical development team selected an integrated solution from BioClinica that will seamlessly share essential clinical data while streamlining their clinical data and site management processes," said Peter Benton, BioClinica's President of eClinical Solutions. "In the last two quarters we have seen sponsors and CROs significantly increase their interest and investment in solutions that are not only "best-in-class" but also reduce the cost and hassle of unifying their clinical data to both manage their trials as well as readying their data for analysis."